We investigated the performance of the US stock market and factors on, and around, GDP release events. Read more here.
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 422.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results